TABLE 2.
Antimicrobial resistance characteristics among 63 multidrug-resistant E. coli isolates from community hospitals
| Antimicrobial category | Resistance gene/antimicrobial agent | No. (column %) of isolates |
P valuec |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (n = 63) | ST131 (n = 39) | Non-ST131 (n = 24) | ST131 H30Rx (n = 27) | ST131 non-H30Rx (n = 12) | All non-H30Rx (n = 36) | ST131 vs non-ST131 | H30Rx vs non-H30Rx ST131 | H30Rx vs all non-H30Rx | ||
| Beta-lactam | blaCTX-M-9 | 1 (2) | 0 | 1 (4) | 0 | 0 | 1 (3) | |||
| blaCTX-M-14 | 11 (17) | 4 (10) | 7 (29) | 0 | 4 (33) | 11 (31) | 0.006 | 0.002 | ||
| blaCTX-M-15 | 39 (62) | 27 (69) | 12 (50) | 26 (96) | 1 (8) | 13 (36) | <0.001 | <0.001 | ||
| blaCTX-M-27 | 1 (2) | 1 (3) | 0 | 0 | 1 (8) | 1 (3) | ||||
| Any CTX-M | 51 (81) | 31 (79) | 20 (83) | 26 (96) | 5 (42) | 25 (69) | <0.001 | 0.009 | ||
| Aminoglycoside | aadA1 | 4 (6) | 4 (10) | 0 | 4 (15) | 0 | 0 | 0.03 | ||
| aadA5 | 45 (71) | 30 (77) | 15 (63) | 23 (85) | 7 (58) | 22 (61) | 0.05 | |||
| strA | 28 (44) | 13 (33) | 15 (63) | 7 (26) | 6 (50) | 21 (58) | 0.04 | 0.01 | ||
| strB | 27 (43) | 12 (31) | 15 (63) | 6 (22) | 6 (50) | 21 (58) | 0.02 | 0.005 | ||
| PMQRa | aac(6′)-Ib-cr | 25 (40) | 16 (41) | 9 (38) | 15 (56) | 1 (8) | 10 (28) | 0.01 | 0.04 | |
| qnrS1 | 1 (2) | 0 | 1 (4) | 0 | 0 | 1 (3) | ||||
| QRDRb | 1A1B1, gyrA | 37 (59) | 37 (95) | 0 | 27 (100) | 10 (83) | 10 (28) | <0.001 | <0.001 | |
| 20A1B1, gyrA | 8 (13) | 0 | 8 (33) | 0 | 0 | 8 (22) | <0.001 | 0.008 | ||
| 1a1A1B1, parC | 37 (59) | 37 (95) | 0 | 27 (100) | 10 (83) | 10 (28) | <0.001 | <0.001 | ||
| 5A1, parC | 11 (17) | 0 | 11 (46) | 0 | 0 | 11 (31) | <0.001 | 0.002 | ||
| 3L, parE | 39 (62) | 39 (100) | 0 | 27 (100) | 12 (100) | 12 (33) | <0.001 | <0.001 | ||
| 1A1, parE | 9 (14) | 0 | 9 (38) | 0 | 0 | 9 (25) | <0.001 | 0.008 | ||
| Sulfonamide | sul1 | 49 (78) | 32 (82) | 17 (71) | 24 (89) | 8 (67) | 25 (69) | |||
| sul2 | 28 (44) | 13 (33) | 15 (63) | 7 (26) | 6 (50) | 21 (58) | 0.04 | 0.01 | ||
| Trimethoprim | dfrA17 | 45 (71) | 30 (77) | 15 (63) | 23 (85) | 7 (58) | 22 (61) | 0.05 | ||
| Phenicol | catA1 | 5 (8) | 0 | 5 (21) | 0 | 0 | 5 (14) | 0.006 | ||
| catB3 | 25 (40) | 17 (44) | 8 (33) | 16 (59) | 1 (8) | 9 (25) | 0.005 | 0.009 | ||
| Tetracycline | tet(A) | 31 (49) | 23 (59) | 8 (33) | 17 (63) | 6 (50) | 14 (39) | |||
| tet(B) | 10 (16) | 0 | 10 (42) | 0 | 0 | 10 (28) | <0.001 | 0.003 | ||
| Phenotype | Gentamicin | 21 (33) | 12 (31) | 9 (38) | 8 (30) | 4 (33) | 13 (36) | |||
| Amikacin | 9 (14) | 7 (18) | 2 (8) | 7 (26) | 0 | 2 (6) | 0.03 | |||
| Ciprofloxacin | 56 (89) | 37 (95) | 19 (79) | 27 (100) | 10 (83) | 29 (81) | 0.02 | |||
| Levofloxacin | 55 (87) | 37 (95) | 18 (75) | 27 (100) | 10 (83) | 28 (78) | 0.05 | 0.008 | ||
| Trimethoprim-sulfamethoxazole | 49 (78) | 32 (82) | 17 (71) | 24 (89) | 8 (67) | 25 (69) | ||||
| Ampicillin-sulbactam | 55 (87) | 34 (87) | 21 (88) | 25 (93) | 9 (75) | 30 (83) | ||||
| Piperacillin-tazobactam | 24 (38) | 16 (41) | 8 (33) | 16 (59) | 0 | 8 (22) | <0.001 | 0.004 | ||
| Ceftriaxone | 52 (83) | 31 (79) | 21 (88) | 26 (96) | 5 (42) | 26 (72) | <0.001 | 0.02 | ||
| Cefepime | 46 (73) | 26 (67) | 20 (83) | 22 (81) | 4 (33) | 24 (67) | 0.008 | |||
| Ertapenem | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Imipenem | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Minocycline | 13 (21) | 2 (5) | 11 (46) | 1 (4) | 1 (8) | 12 (33) | <0.001 | 0.004 | ||
a
PMQR, plasmid-mediated quinolone resistance.
b
1A1B1, S83L/D87N; 20A1B1, S83L/D87N; 1a1A1B1, c321g/S80I/E84V; 5A1, S80I; 3L, I529L; 1A1, S458A.
c
Only P values of <0.05 are shown.